Literature DB >> 16464532

Management of BCG failures in superficial bladder cancer: a review.

Johannes A Witjes1.   

Abstract

OBJECTIVE: Review management of bacillus Calmette-Guérin (BCG) failures in superficial bladder cancer.
METHOD: Search of published literature and meeting abstracts.
RESULTS: Patients in whom BCG fails are not a uniform group. Failure cannot be predicted but high-risk patients can be identified. In case of failure and progression the outcome is bad. Conservative but investigative alternatives are BCG/interferon-alpha, intravesical hyperthermia/chemotherapy, or photodynamic therapy. Standard treatment in failing patients remains cystoprostatectomy.
CONCLUSION: BCG failures need careful and individualized therapy in experienced hands.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16464532     DOI: 10.1016/j.eururo.2006.01.017

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  39 in total

Review 1.  New therapies for non-muscle-invasive bladder cancer.

Authors:  Edmund Chiong; Kesavan Esuvaranathan
Journal:  World J Urol       Date:  2009-09-18       Impact factor: 4.226

2.  Enhanced antitumor effect of combination intravesical mitomycin C and bacillus Calmette-Guerin therapy in an orthotopic bladder cancer model.

Authors:  Masashi Matsushima; Minoru Horinaga; Ryuichi Fukuyama; Hitoshi Yanaihara; Eiji Kikuchi; Makoto Kawachi; Masahiro Iida; Yoko Nakahira; Mototsugu Oya; Hirotaka Asakura
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

Review 3.  Modeling human bladder cancer.

Authors:  Cassandra Ringuette-Goulet; Stéphane Bolduc; Frédéric Pouliot
Journal:  World J Urol       Date:  2018-06-14       Impact factor: 4.226

4.  Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.

Authors:  Rafael Nunez-Nateras; Erik P Castle; Cheryl A Protheroe; Melissa L Stanton; Tolgay I Ocal; Erin N Ferrigni; Sergei I Ochkur; Elizabeth A Jacobsen; Yue-Xian Hou; Paul E Andrews; Thomas V Colby; Nancy A Lee; James J Lee
Journal:  Urol Oncol       Date:  2013-09-18       Impact factor: 3.498

5.  The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis.

Authors:  Min Yang; Mihaela V Georgieva; Iryna Bocharova; Mohini Vembusubramanian; Kun Qian; Amy Guo; Ashish M Kamat
Journal:  Adv Ther       Date:  2021-01-11       Impact factor: 3.845

Review 6.  Effect of anticoagulants and antiplatelet agents on the efficacy of intravesical BCG treatment of bladder cancer: A systematic review.

Authors:  Nader Fahmy; Alejandro Lazo-Langner; Alla E Iansavichene; Stephen E Pautler
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

7.  The management of BCG failure in non-muscle-invasive bladder cancer: an update.

Authors:  Alexandre R Zlotta; Neil E Fleshner; Michael A Jewett
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

8.  The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial.

Authors:  Maximilian Burger; Nicolas Thiounn; Stefan Denzinger; Jozsef Kondas; Gerard Benoit; Manuel S Chapado; Fernando J Jimenz-Cruz; Laszlo Kisbenedek; Zoltán Szabo; Domján Zsolt; Marc O Grimm; Imre Romics; Joachim W Thüroff; Tamas Kiss; Bertrand Tombal; Manfred Wirth; Marc Munsell; Bonnie Mills; Tung Koh; Jeff Sherman
Journal:  J Transl Med       Date:  2010-06-08       Impact factor: 5.531

9.  BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis.

Authors:  Katja Schwarzer; Martin Foerster; Thomas Steiner; Inge-Marie Hermann; Eberhard Straube
Journal:  Cancer Cell Int       Date:  2010-06-29       Impact factor: 5.722

10.  SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.

Authors:  Eila C Skinner; Bryan Goldman; Wael A Sakr; Daniel P Petrylak; Heinz-Josef Lenz; Cheryl T Lee; Shandra S Wilson; Mitchell Benson; Seth P Lerner; Cathy M Tangen; Ian M Thompson
Journal:  J Urol       Date:  2013-04-15       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.